AR018772A1 - Composicion farmaceutica para prevenir o tratar depresion, inquietud, enfermedad maniaca depresiva o psicopatia, compuesto heterociclico comprendido en lamisma, prodroga obtenida a partir del anterior, metodo para producir dicho compuesto y su uso - Google Patents
Composicion farmaceutica para prevenir o tratar depresion, inquietud, enfermedad maniaca depresiva o psicopatia, compuesto heterociclico comprendido en lamisma, prodroga obtenida a partir del anterior, metodo para producir dicho compuesto y su usoInfo
- Publication number
- AR018772A1 AR018772A1 ARP990101177A ARP990101177A AR018772A1 AR 018772 A1 AR018772 A1 AR 018772A1 AR P990101177 A ARP990101177 A AR P990101177A AR P990101177 A ARP990101177 A AR P990101177A AR 018772 A1 AR018772 A1 AR 018772A1
- Authority
- AR
- Argentina
- Prior art keywords
- ring
- group
- pharmaceutical composition
- optionally substituted
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 208000024823 antisocial personality disease Diseases 0.000 title abstract 2
- 206010026749 Mania Diseases 0.000 title 1
- 230000003001 depressive effect Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 208000001431 Psychomotor Agitation Diseases 0.000 abstract 1
- 206010038743 Restlessness Diseases 0.000 abstract 1
- 102000007124 Tachykinin Receptors Human genes 0.000 abstract 1
- 108010072901 Tachykinin Receptors Proteins 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 abstract 1
- 208000028683 bipolar I disease Diseases 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 238000007363 ring formation reaction Methods 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Una composicion farmacéutica para prevenir o tratar depresion, inquietud, enfermedad maníaca depresiva o psicopatía que comprende un compuestoheterocíclico representado por la formula (I), en donde el anillo M es un anillo heterocíclico en donde -X =Y < es uno de -N=C<, -CO-N< o -CS-N<,Ra y Rb están enlazados el uno al otro para formar anillo A o éstos son iguales o diferentes y representan, independientemente, un átomo de hidrogenoo un sustituyente sobre el anillo M; el anillo A y el anillo Brepresenta, independientemente, un anillo homocíclico o heterocíclico opcionalmentesustituido, con la condicion que por lo menos uno de los dos es un anillo heterocícliclo opcionalmente sustituido; el anillo C es un anillo homocíclicoo heterocíclicoopcionalmente sustituido; el anillo Z es un anillo heterocíclico conteniendo nitrogeno opcionalmente sustituido; y n es un entero devalor 1 a 6, o una sal del mismo, que posee una accion antagonica al receptor de taquiquinina. Un compuesto heterocíclico representado por la formula (II),en donde R1 es un grupo alquilo C1-6; R2 es un grupo alcoxilo C1-6, grupo alquilo C1-6 opcionalmente halogenado, un átomo de halogeno, un grupohidroxilo o un grupo aralquiloxilo C7-15; X son 1 a 5 grupos seleccionados del grupo que consiste de un átomo de hidrogeno, un grupo alquilo C1-6 y unátomo de halogeno, con la condicion que (1) R1 es un grupo metilo y R2 es grupo trifluorometilo; X es un átomo de halogeno y (2) cuando R1 es ungrupo metilo y R2 es un grupo metoxilo; X es un átomo de hidrogeno o un átomo de halogeno o una sal del mismo. Una prodroga que se realiza con uncompuesto de acuerdo con el descripto. Un método para producir dicho compuesto por ciclacion de un compuesto de formula (III), en donde D y E representanlos grupos desde los cuales un grupo representado por la formula (IV) se forman junto con el átomo de nitrogeno adyacente a E; L representa un grupode comienzo y los otros símbolos poseen los mismos significados anteriormente descriptos, o una sal del mismo. Una composicion farmacéutica para prevenir
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6999998 | 1998-03-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR018772A1 true AR018772A1 (es) | 2001-12-12 |
Family
ID=13418890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990101177A AR018772A1 (es) | 1998-03-19 | 1999-03-18 | Composicion farmaceutica para prevenir o tratar depresion, inquietud, enfermedad maniaca depresiva o psicopatia, compuesto heterociclico comprendido en lamisma, prodroga obtenida a partir del anterior, metodo para producir dicho compuesto y su uso |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP1184036A2 (es) |
| KR (1) | KR20010041991A (es) |
| CN (1) | CN1291099A (es) |
| AR (1) | AR018772A1 (es) |
| AU (1) | AU751114B2 (es) |
| BR (1) | BR9908895A (es) |
| CA (1) | CA2321155A1 (es) |
| HU (1) | HUP0100934A3 (es) |
| ID (1) | ID25818A (es) |
| IL (1) | IL136950A0 (es) |
| NO (1) | NO20004144L (es) |
| WO (1) | WO1999047132A2 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI287003B (en) | 2000-07-24 | 2007-09-21 | Hoffmann La Roche | 4-phenyl-pyridine derivatives |
| CA2423364A1 (en) * | 2000-09-26 | 2003-03-25 | Takeda Chemical Industries, Ltd. | Preventives/remedies for emotional disorders |
| EP1591120A4 (en) * | 2003-01-28 | 2009-06-10 | Takeda Chemical Industries Ltd | RECEPTOR AGONISTS |
| EP2322222A4 (en) | 2008-08-07 | 2011-12-21 | Takeda Pharmaceutical | THERAPEUTIC FOR IRRITATION SYNDROME |
| CN105940002B (zh) | 2014-02-03 | 2018-09-25 | 生命医药公司 | ROR-γ的二氢吡咯并吡啶抑制剂 |
| DK3207043T6 (da) | 2014-10-14 | 2020-01-20 | Vitae Pharmaceuticals Llc | Dihydropyrrolopyridin-inhibitorer af ror-gamma |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| US10301261B2 (en) | 2015-08-05 | 2019-05-28 | Vitae Pharmaceuticals, Llc | Substituted indoles as modulators of ROR-gamma |
| AU2016355710B2 (en) | 2015-11-20 | 2021-03-25 | Vitae Pharmaceuticals, Llc | Modulators of ROR-gamma |
| TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| SG11202000621VA (en) | 2017-07-24 | 2020-02-27 | Vitae Pharmaceuticals Llc | Inhibitors of ror? |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE9290063U1 (de) * | 1991-05-31 | 1994-02-24 | Pfizer Inc., New York, N.Y. | Chinuclidin-Derivate |
| DE69628484T2 (de) * | 1995-03-24 | 2004-05-19 | Takeda Chemical Industries, Ltd. | Zyklische Verbindungen, ihre Herstellung und ihre Verwendung als Tachykininrezeptorantagonisten |
-
1999
- 1999-03-18 ID IDW20001579A patent/ID25818A/id unknown
- 1999-03-18 KR KR1020007010318A patent/KR20010041991A/ko not_active Withdrawn
- 1999-03-18 AR ARP990101177A patent/AR018772A1/es unknown
- 1999-03-18 HU HU0100934A patent/HUP0100934A3/hu unknown
- 1999-03-18 CN CN99803086A patent/CN1291099A/zh active Pending
- 1999-03-18 EP EP01127194A patent/EP1184036A2/en not_active Withdrawn
- 1999-03-18 IL IL13695099A patent/IL136950A0/xx unknown
- 1999-03-18 EP EP99909233A patent/EP1061926A2/en not_active Withdrawn
- 1999-03-18 CA CA002321155A patent/CA2321155A1/en not_active Abandoned
- 1999-03-18 BR BR9908895-9A patent/BR9908895A/pt not_active IP Right Cessation
- 1999-03-18 AU AU28532/99A patent/AU751114B2/en not_active Ceased
- 1999-03-18 WO PCT/JP1999/001358 patent/WO1999047132A2/en not_active Ceased
-
2000
- 2000-08-18 NO NO20004144A patent/NO20004144L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20004144L (no) | 2000-10-10 |
| ID25818A (id) | 2000-11-09 |
| HUP0100934A2 (hu) | 2001-09-28 |
| CA2321155A1 (en) | 1999-09-23 |
| EP1061926A2 (en) | 2000-12-27 |
| IL136950A0 (en) | 2001-06-14 |
| EP1184036A2 (en) | 2002-03-06 |
| HUP0100934A3 (en) | 2002-09-30 |
| NO20004144D0 (no) | 2000-08-18 |
| AU751114B2 (en) | 2002-08-08 |
| AU2853299A (en) | 1999-10-11 |
| CN1291099A (zh) | 2001-04-11 |
| BR9908895A (pt) | 2000-12-05 |
| WO1999047132A3 (en) | 1999-11-11 |
| WO1999047132A2 (en) | 1999-09-23 |
| KR20010041991A (ko) | 2001-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR018772A1 (es) | Composicion farmaceutica para prevenir o tratar depresion, inquietud, enfermedad maniaca depresiva o psicopatia, compuesto heterociclico comprendido en lamisma, prodroga obtenida a partir del anterior, metodo para producir dicho compuesto y su uso | |
| RU2495873C2 (ru) | Новое урациловое соединение или его соль, обладающие ингибирующей активностью относительно дезоксиуридинтрифосфатазы человека | |
| ATE334973T1 (de) | Chinazolinverbindungen | |
| NO20004624L (no) | Benzensulfonamid-derivater og deres anvendelse som medikamenter | |
| NO953447L (no) | Nye 4-aminopyridiner, fremgangsmåte for deres fremstilling samt legemidler inneholdende disse | |
| SE8004253L (sv) | Nya 4-aroylimidazol-2-oner | |
| BR0213646A (pt) | Método, compostos e composição para controle de pragas invertebradas | |
| AU6798190A (en) | Serotonin antagonists, their preparation and compositions containing them | |
| AR030203A1 (es) | Derivados de carbamato de 2-(s)-hidroximutilina, composiciones farmaceuticas que los comprenden, procedimiento para prepararlos y 2(s), 11-dihidroxi protegida-mutilina como compuesto intermediario | |
| AR019167A1 (es) | Derivados heteroaromaticos de piperazinas di-n-sustituidas y piperidinas 1,4-disustituidas, composiciones farmaceuticas y el uso de los mismos para lapreparacion de medicamentos | |
| DK0992509T3 (da) | Nye makrolid-derivater | |
| EA200100090A2 (ru) | Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции | |
| FR2804958B1 (fr) | Derives de xanthine, leur procede de preparation et les intermediaires de ce procede, leur application comme medicament et les compositions pharmaceutiques les renfermant | |
| AR012883A1 (es) | Compuestos derivados de ciclobutilamina sustituida, composicion farmaceutica y agente antibacteriano. | |
| MX9304403A (es) | Derivados farmacologicamente activos de ó-(aminometilo terciario)-bencenmetanol | |
| EA200101170A1 (ru) | Галоидпроизводные 9-деоксо-9а-аза-9а-гомоэритромицина а | |
| KR960706492A (ko) | 3-치환 1-아릴인돌 화합물 (3-substituted 1-arylindole compounds) | |
| ES500810A0 (es) | Procedimiento de preparacion de aminoalcoxipirazoles | |
| DE69620175D1 (de) | Hydroxylamin-derivate mit anti-ischämischer wirkung und pharmazeutische zusammensetzungen diese enthaltend | |
| BR0311956A (pt) | Derivados de 3-(4-oxo-4h-cromen-2-il)(1h)-quinoleìn-4-onas, o respectivo processo de preparo e as composições farmacêuticas que os contêm | |
| NO862494D0 (no) | Fremgangsmaate for fremstilling av nye aromatiske forbindelser. | |
| DE60335960D1 (de) | 1,2,4-triazolderivat, verfahren zu dessenherstellung, und dieses enthaltende pharmazeutische zusammensetzung | |
| ATE92058T1 (de) | Pyrimidin-derivate, 2-(4-(alpha-heteroaryl-alphaaryl-(alpha-alkyl)-methoxy)-butyl)-1-piperaziny > mit serotoninergischer wirkung. | |
| BR0201312A (pt) | Compostos de pirimidin-4-ona, processo para sua preparação e composições farmacêuticas contendo os referidos | |
| PT93904A (pt) | Processo para a preparacao de novos derivados benzotiazolinonicos e de composicoes farmaceuticas que os contem |